<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Bone marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> is associated with a poor outcome, but whether the outcome after allogeneic stem cell transplantation is related to the degree of bone marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND METHODS: Patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and known bone marrow histology (n=721) who underwent hematopoietic stem cell transplantation were classified according to the degree of bone marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> into those without <z:mp ids='MP_0003045'>fibrosis</z:mp> (n=483), those with mild or moderate <z:mp ids='MP_0003045'>fibrosis</z:mp> (n=199) and those with severe <z:mp ids='MP_0003045'>fibrosis</z:mp> (n=39) and analyzed regarding engraftment, treatment-related mortality, relapse and survival </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The degree of <z:mp ids='MP_0003045'>fibrosis</z:mp> was not associated with disease status or abnormal cytogenetics </plain></SENT>
<SENT sid="3" pm="."><plain>The cumulative incidence of engraftment achieved at day +30 in non-fibrotic patients was 93% and was significantly lower in those with mild or moderate <z:mp ids='MP_0003045'>fibrosis</z:mp> (89%) and severe <z:mp ids='MP_0003045'>fibrosis</z:mp> (75%) (P=0.009) </plain></SENT>
<SENT sid="4" pm="."><plain>Neutrophil engraftment occurred later in patients with mild or moderate <z:mp ids='MP_0003045'>fibrosis</z:mp> and severe <z:mp ids='MP_0003045'>fibrosis</z:mp> than in patients without <z:mp ids='MP_0003045'>fibrosis</z:mp> (median 17 versus 20 versus 16 days, respectively; P=0.002) </plain></SENT>
<SENT sid="5" pm="."><plain>The cumulative incidence of relapse at 3 years was significantly higher in patients with severe <z:mp ids='MP_0003045'>fibrosis</z:mp> than in those with a lesser degree of <z:mp ids='MP_0003045'>fibrosis</z:mp> or no <z:mp ids='MP_0003045'>fibrosis</z:mp> (47% versus 28% versus 27%, respectively; P=0.04), resulting in comparable 3-year disease-free survival rates in patients without <z:mp ids='MP_0003045'>fibrosis</z:mp> and in those with mild or moderate <z:mp ids='MP_0003045'>fibrosis</z:mp> (42% versus 38%, respectively) but a lower disease-free survival rate in those with severe <z:mp ids='MP_0003045'>fibrosis</z:mp> (18%; P=0.002) </plain></SENT>
<SENT sid="6" pm="."><plain>Severe <z:mp ids='MP_0003045'>fibrosis</z:mp> remained an independent factor for reduced survival (hazard ratio, 1.9; P=0.006) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Among patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, only severe <z:mp ids='MP_0003045'>fibrosis</z:mp> affects survival after hematopoietic stem cell transplantation while patients with mild or moderate <z:mp ids='MP_0003045'>fibrosis</z:mp> have an outcome comparable to that of patients without bone marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
</text></document>